Rubicon Research Ltd

Stage 2 · Advancing · week 9Setup 4.1 WatchSolid +0.8

As of 9 Oct 2026, Rubicon Research is in Stage 2 — advancing, the uptrend phase, in week 9 (since 10 Aug 2026). It closed at ₹1,549, above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. More about the company

₹1,548.5
+0.85% today
₹25,633 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

4.1 Watch

Momentum

Steady

Edge

Solid +0.8

Setup-score rank among Stage 2 peers: #48 of 61 in Pharmaceuticals · #58 of 78 in Health Care

Is RUBICON early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
—
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 9
1w13w26w
Week 9 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
35.5%
200 DMA: ₹1,143.1 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.45x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -5.9% vs MA50 +5.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-16.8%
3M
+8.2%
6M
+93.9%
YTD
+125.3%
1Y
—
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Stage Cycle Timeline2025-10-16 → 2026-10-09
S? 42w
S2 9w
2025-10-162026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S2 9w current
Total tracked: 51 weeks across 2 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-08-10
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 9 · Vol 0.45x
2026-10-08S2
Wk 9 · Vol 0.32x
2026-10-07S2
Wk 9 · Vol 0.44x
2026-10-06S2
Wk 8 · Vol 0.21x
2026-10-05S2
Wk 8 · Vol 0.46x
2026-10-01S2
Wk 8 · Vol 0.44x
2026-09-30S2
Wk 8 · Vol 0.65x
2026-09-29S2
Wk 8 · Vol 2.05x
2026-09-28S2
Wk 7 · Vol 0.63x
2026-09-25S2
Wk 7 · Vol 0.37x
2026-09-24S2
Wk 7 · Vol 0.78x
2026-09-23S2
Wk 7 · Vol 1.76x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
SHILPAMED
wk 22 · -4.8% from hi
7.6
Moving averages & range
50 DMA
₹1,691.4
200 DMA
₹1,143.1
52W High
—
52W Low
—
5D Low
₹1,535.4
Resistance levels (recent highs)
20d High
₹1,835.4
60d High
₹1,860.6
120d High
₹1,860.6
250d High
—
Next resistance
+18.5%
to 20d High
Ask the Market AI about RUBICONAsk →
P/E (TTM)
77.3
Forward 48.8
Earnings Growth (YoY)
+79.3%
Revenue +51.7%
About this companyHealth Care· Pharmaceuticals

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.